Log in

NASDAQ:BBHVanEck Vectors Biotech ETF Stock Price, Forecast & News

-0.72 (-0.45 %)
(As of 06/2/2020 04:00 PM ET)
Today's Range
Now: $160.19
50-Day Range
MA: $151.86
52-Week Range
Now: $160.19
Volume29,300 shs
Average Volume28,129 shs
Market Capitalization$464.07 million
P/E RatioN/A
Dividend Yield0.29%

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.81 out of 5 stars

Basic Details

Issuer Van Eck
Fund NameVanEck Vectors Biotech ETF
Tax ClassificationRegulated Investment Company
Inception Date12/20/2011
Fund ManagerHao-Hung Peter Liao, Guo Hua Jason Jin

Fund Focus

Asset ClassEquity
BenchmarkMarket Vectors US Listed Biotech 25 Index
FocusHealth Care
Development LevelDeveloped Markets

Fund Statistics

Assets Under Management$1.92 billion
Average Daily Volume$14,048.50

ETF Expenses

Management Fee0.35%
Other Expenses0.04%
Total Expenses0.39%
Fee Waiver-0.04%
Net Expenses0.35%

Administrator, Advisor and Custodian

AdministratorVan Eck Associates Corporation
AdvisorVan Eck Associates Corporation
CustodianThe Bank of New York Mellon Corporation
DistributorVan Eck Securities Corporation
Transfer AgentThe Bank of New York Mellon Corporation
Lead Market MakerVirtu Financial

Receive BBH News and Ratings via Email

Sign-up to receive the latest news and ratings for BBH and its competitors with MarketBeat's FREE daily newsletter.

Geographic Exposure of VanEck Vectors Biotech ETF (NASDAQ:BBH)
Currency Exposure of VanEck Vectors Biotech ETF (NASDAQ:BBH)
Sector Exposure of VanEck Vectors Biotech ETF (NASDAQ:BBH)
Industry Exposure of VanEck Vectors Biotech ETF (NASDAQ:BBH)

VanEck Vectors Biotech ETF (NASDAQ:BBH) Frequently Asked Questions

How has VanEck Vectors Biotech ETF's stock been impacted by COVID-19 (Coronavirus)?

VanEck Vectors Biotech ETF's stock was trading at $126.82 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BBH stock has increased by 26.3% and is now trading at $160.19. View which stocks have been most impacted by Coronavirus.

Has VanEck Vectors Biotech ETF been receiving favorable news coverage?

Media stories about BBH stock have been trending negative recently, according to InfoTrie. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. VanEck Vectors Biotech ETF earned a daily sentiment score of -2.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutVanEck Vectors Biotech ETF.

Who are some of VanEck Vectors Biotech ETF's key competitors?

What other stocks do shareholders of VanEck Vectors Biotech ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VanEck Vectors Biotech ETF investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Marina Biotech (MRNA), Sanofi (SNY), Cidara Therapeutics (CDTX), Quest Diagnostics (DGX), Crispr Therapeutics (CRSP), Johnson & Johnson (JNJ), Matinas BioPharma (MTNB) and Micron Technology (MU).

What is VanEck Vectors Biotech ETF's stock symbol?

VanEck Vectors Biotech ETF trades on the NASDAQ under the ticker symbol "BBH."

Who are VanEck Vectors Biotech ETF's major shareholders?

VanEck Vectors Biotech ETF's stock is owned by a number of institutional and retail investors. Top institutional investors include Morgan Stanley (1.67%), Morgan Stanley (1.56%), UBS Group AG (1.71%), Murphy Capital Management Inc. (1.38%), Mogy Joel R Investment Counsel Inc. (0.83%) and Envestnet Asset Management Inc. (0.58%).

Which institutional investors are selling VanEck Vectors Biotech ETF stock?

BBH stock was sold by a variety of institutional investors in the last quarter, including Raymond James & Associates, Bank of New York Mellon Corp, Mogy Joel R Investment Counsel Inc., Ironsides Asset Advisors LLC, UBS Group AG, Murphy Capital Management Inc., Aspiriant LLC, and Wells Fargo & Company MN.

Which institutional investors are buying VanEck Vectors Biotech ETF stock?

BBH stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Columbus Macro LLC, PNC Financial Services Group Inc., Advisor Group Holdings Inc., CIBC World Markets Inc., CAPROCK Group Inc., Cambridge Investment Research Advisors Inc., and HighTower Advisors LLC.

How do I buy shares of VanEck Vectors Biotech ETF?

Shares of BBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is VanEck Vectors Biotech ETF's stock price today?

One share of BBH stock can currently be purchased for approximately $160.19.

How big of a company is VanEck Vectors Biotech ETF?

VanEck Vectors Biotech ETF has a market capitalization of $464.07 million.

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.